Pulmonary hypertension is serious life threatening condition characterized by an increase in blood pressure in the pulmonary artery or vein. It is can result in shortness of breath, dizziness and fainting. In severe cases, patients have severely decreased exercise tolerance and heart failure.
Treatment options to date have included a large number of medication’s including calcium channel blockers, prostaglandins, endothelin receptor anatagonists and phosphodiesterase inhibitors. Median survival rate in patients untreated is 2-3 years from time of diagnosis. Unfortunately for those patients who have failed conventional therapy, there has been no treatment options until recently.
Dr. Grekos reported significant clinical success utilizing adult stem cell therapy in treating pulmonary hypertension. Dr. Grekos notes: This is the first time medical science has successfully reversed the disease process in pulmonary hypertension, a previously untreatable condition with a very grim prognosis,”
Unfortunately such therapy may not be available if the FDA continues to exert its jurisdiction. The FDA contends that a patient’s own stem cells are a biologic drug over which they have jurisdiction. A physician based organization has been formed which established both clinical and laboratory guidelines for the safe use of adult stem cell therapy: stemcelldocs.org